

NATIONAL PATIENT GROUP DIRECTION FOR URGENT PROVISION OF MEDICINES, APPLIANCES AND ACBS PRODUCTS.

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS.

IT IS THE RESPONSIBILITY OF THE INDIVIDUAL TO ENSURE THEY ARE USING THE MOST UP TO DATE PGD

1. Authorisation

Developed on behalf of NHS Scotland by NHS 24 by:

| Physician | Dr Laura Ryan | Signature | Laure 12/2 |
|--------------------------------|--------------------------|-----------|----------------------|
| Pharmacist | Dr John McAnaw | Signature | John War |
| NHS Scotland Representative | Mr Jim Miller | Signature | for holler |
| | | | |
| Authorised for use | on behalf of | GGC | Health Board by |
| Medical Director | Dr Jennifer Armstrong | Signature | g. S. Smittag |
| Senior Pharmacist | Alan Harrison | Signature | Chambrings |
| Clinical Governance Lead | Aileen Muir | Signature | Alach. |
| Date Approved | May 2023 | | |
| Effective from | April 2023 | | Expires October 2024 |



2. Management of the Patient Group Direction (PGD)

This PGD must be read, agreed to and signed by all pharmacists involved in its use. The original signed copy should be held by the Health Board.

3. Application

This PGD covers the urgent provision of current NHS prescribed medicines, appliances and ACBS products to NHS patients by pharmacists where there is a clinical need, it is clinically appropriate to make the supply and when the patient's prescriber is unavailable.

4. Clinical Condition

| Situation | The provision from a pharmacy with an NHS contract of NHS prescribed medicines, appliances and ACBS products required when the patient is unable to obtain a prescription for supply in the normal way for the clinical conditions described in part A in the schedules of this PGD. |
|--------------------|--|
| Inclusion Criteria | Medicines and/or appliances and/or ACBS products requested by patient and are currently being prescribed by patient's prescriber (see Note 1). |
| | Medicines and/or appliances and/or ACBS products are allowed on NHS prescription and are not listed in part B in the schedules of this PGD. |
| | The prescriber is unavailable. |
| | Patient is registered (or temporarily) with a medical practice in Scotland. |
| | Patient agrees to relevant clinical information being provided to the pharmacist. |
| | Patient agrees that all relevant clinical information is shared between their prescriber and the pharmacist. |
| Exclusion Criteria | Provision is not urgent. |
| | Medicines and/or appliances and/or ACBS products which are listed in part B in the schedules of this PGD or are not allowed on NHS prescription. |
| | No agreement to share relevant clinical information. |
| | Patient's clinical condition significantly changed. |
| Action if Excluded | Provide supply under existing emergency supply regulations. |
| | Refer to prescriber or to OOH service using the direct referral process if emergency supply regulations do not apply. |



Note 1

The PGD not only covers the urgent supply of a repeat prescription item, but permits the supply of a medicine in a number of other situations thereby bringing it into line with current emergency supply regulations. Below are some scenarios where an urgent supply can be given supporting continuity of patient care (not an exhaustive list):

- Patient recently discharged from hospital with new medication and has not organised a further supply of medication with their own prescriber who is now unavailable
- Acute prescribed medication that has been lost, stored incorrectly, or smashed bottle
- Medication that is prescribed regularly but may not be on a repeat prescription for example antidepressants
- Patient has been prescribed an acute medication, but prescription has not been forwarded/received in the pharmacy and prescriber unavailable – information held on Emergency Care Summary (ECS) obtained directly by the pharmacy or through NHS 24 would enable supply *
- Patient prescribed medication which they cannot swallow, and they require a liquid preparation
- Alternative flavour of same antibiotic if child unable to tolerate dispensed medication, or indeed capsule or tablet formulation if this resolves the situation
- Supply alternative formulation if dispensed medication is not suitable for other reasons e.g. allergy to excipient, religious reason e.g. beef gelatine
- Acute supplies of rescue antibiotic for COPD patients, many patients keep rescue antibiotic prescription but may have used the last one without renewing it
- Dispense remaining balance of antibiotic when original dispensing pharmacy is closed

^{*} If you are unable to access ECS, then please contact your Health Board to have this rectified. Details of individual Health Boards can be found on the NHS Community Pharmacy website via the following link contact your Health Board. There is also guidance on accessing/troubleshooting ECS on the Community Pharmacy Scotland (cps.scot) website.



5. Description of Treatment

| Medicine | All medicines and/or appliances and/or ACBS products required and listed in BNF and BNFC described in part A in the schedules of this PGD. |
|--------------------------|--|
| Legal Status | As described in the BNF or BNFC. |
| Dosage Form and Strength | As normally prescribed by the patient's prescriber. |
| | or |
| | Variation of product brand and/or dosage form and/or strength may be substituted when usual product cannot be supplied within a reasonable time provided the active drug base and dose and dosage regimen is equivalent. |
| Dose | As normally prescribed by the patient's prescriber or if not known as recommended by the BNF or BNFC. |
| Exceptions | All medicines and/or appliances and/or ACBS products listed in part B in the schedules of this PGD. |
| Duration of Supply | One prescribing cycle i.e. quantity and duration normally prescribed to patient or up to one month's supply if not known. |
| Patient Information | Provision of the appropriate Pharmaceutical Industry Patient Information Leaflet. |
| | Provision of any other relevant information as judged by the pharmacist operating under this PGD. |
| Documentation | The pharmacist will complete a Universal Claim Framework (UCF) entry within the patient's PMR, producing a completed CP4 form detailing the supply made. |
| Supply | The supply of medicine and/or appliances and/or ACBS products should comply with the requirement for labelling and be in an appropriate container or packaging. |
| Follow-up | Ensure that the patient's prescriber is notified and that all records are completed. |
| Adverse reactions | As described in BNF or BNFC. |



| Record/Audit Trail | The UCF electronic claim is automatically forwarded to NHS NSS for processing |
|--------------------|---|
| | A record of the transaction i.e. CP4 form print out, should be forwarded to the patient's prescriber as soon as possible for information. |
| | A record of the transaction should automatically be entered in the patient's Prescription Medication Record. |

6. Characteristic of Staff

| Qualifications | Pharmacist whose name is currently on the practising section of |
|----------------|---|
| Required | the pharmaceutical register held by the General Pharmaceutical |
| | Council (GPhC). |
| | |
| | |
| | |



SCHEDULE 1

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Gastro-intestinal system, chapter 1

Part A: All medicines in Gastro-intestinal system, chapter 1 of the current BNF/BNFC ¹, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Chronic bowel disorders | Food allergy | Rectal and anal disorders |
|---|--|-----------------------------------|
| Constipation ² and bowel cleansing | Gastro-intestinal smooth muscle spasm | Exocrine pancreatic insufficiency |
| Diarrhoea | Liver disorders and related conditions | Stoma care |
| Gastric acid disorders and ulceration | Obesity | |

Part B: The following medicines listed in Gastro-intestinal system, chapter 1 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|------------------------------|-------------------------------------|
| All injections and infusions | Acute/Specialist use only |
| All section 2.1 | Acute use only |
| Chenodeoxycholic Acid | Specialist use only |
| Cholic Acid | Specialist use only |
| Obeticholic acid | Specialist use only |
| Odevixibat | Specialist use only |
| Opium | Specialist use only/controlled drug |

¹ Supply of azathioprine, ciclosporin, mercaptopurine and methotrexate to treat a condition listed in Section A above is allowed under this section of the PGD (see PGD page14)

² Supply of sodium citrate products for treating constipation is allowed under this section of the PGD



SCHEDULE 2

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Cardiovascular system, chapter 2

Part A: All medicines in Cardiovascular system, chapter 2 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Arrhythmias | Blood pressure conditions | Myocardial ischaemia |
|--------------------|---------------------------|----------------------|
| Bleeding disorders | Heart failure | Oedema |
| Blood clots | Hyperlipidaemia | Vascular disease |

Part B: The following medicines listed in Cardiovascular system, chapter 2 of the current BNF/BNFC may NOT be provided under this PGD.

| Excluded drug | Rationale |
|---|---------------------------|
| All injections, infusions and intravenous | Acute/Specialist use only |
| flushes except: | |
| | |
| injections for self-administration: | |
| Evolocumab | |
| Bemiparin sodium | |
| Dalteparin sodium | |
| Enoxaparin sodium | |
| Tinzaparin sodium | |
| | |
| All section 2.1 | Specialist use only |
| All section 2.2 | Acute/Specialist use only |
| All section 4.1a | Specialist use only |
| All section 4.1c | Specialist use only |
| All section 4.2 except : Midodrine HCl | Specialist use only |
| Vericiguat | Hospital use only |
| Lomitapide | Specialist use only |
| Mexiletine | Specialist use only |



SCHEDULE 3

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Respiratory system, chapter 3

Part A: All medicines in Respiratory system, chapter 3 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Airways disease, obstructive | Conditions affecting sputum viscosity |
|----------------------------------|---------------------------------------|
| Allergic Conditions ³ | Cough and congestion |

Part B: The following medicines listed in Respiratory system, chapter 3 of the current BNF/BNFC may NOT be provided under this PGD.

| Excluded drug | Rationale | |
|---|------------------------------|--|
| All injections ³ and infusions | Acute/Specialist use only | |
| All section 3.1 except: | Specialist/Hospital use only | |
| Dornase alfa | | |
| All section 5 | Specialist/Hospital use only | |
| Berotralstat | Hospital use only | |
| Erdosteine | Acute use only | |
| Grass pollen extract | Specialist use only | |
| House dust mite extract | Specialist use only | |
| Peanut protein | Specialist use only | |
| Oxygen ⁴ | Alternative supply route | |

³ Supply of adrenaline (Emerade® EpiPen® Jext®) for self-administration to treat anaphylaxis is allowed under this schedule of the PGD

⁴ Oxygen supplies should be obtained via Dolby Vivisol on 0800 833 531



SCHEDULE 4

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Nervous system, chapter 4

Part A: All medicines in Nervous system, chapter 4 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Dementia | Nausea and labyrinth disorders | Sleep disorders |
|-------------------------|--|----------------------|
| Mental health disorders | Pain | Substance dependence |
| Movement disorders | Epilepsy and Other Seizure disorders 5 | |

Part B: The following medicines listed in Nervous system, chapter 4 of the current BNF/BNFC may NOT be provided under this PGD.

| Excluded drug | Rationale |
|---|--------------------------------|
| All injections and infusions | Acute/Specialist use only |
| All section 3.2 except: Atomoxetine, Guanfacine | Controlled drug |
| All section 8.3 | Controlled drug/Specialist use |
| Aprepitant | Specialist use only |
| Buprenorphine | Controlled drug |
| Cannabidiol | Specialist use only |
| Capsaicin patches | Specialist use only |
| Clobazam ⁶ | Epilepsy only |
| Clozapine ⁷ | Registration required |
| Codeine phosphate oral solution | Potential for abuse |
| Dipipanone hydrochloride with cyclizine | Controlled drug |
| Fenfluramine | Specialist use only |
| Fentanyl | Controlled drug |
| Gabapentin | Controlled drug |
| Hydromorphone hydrochloride | Controlled drug |
| Loxapine | Specialist/Hospital use only |
| Methoxyflurane | Close medical supervision only |
| Midazolam ⁸ | Controlled drug |
| Morphine ⁹ | Controlled drug |
| Morphine with cyclizine | Controlled drug |
| Nabilone | Controlled drug/Hospital Use |
| Oxycodone Hydrochloride | Controlled drug |
| Oxycodone with naloxone | Controlled drug |
| Palonosetron | Specialist use only |
| Palonosetron with netupitant | Specialist use only |
| Paracetamol with tramadol | Controlled drug |

Unscheduled Care – Pharmacy Guide – PGD v30

Due for review April 2024

NOT FOR AMENDMENT.

from April 2023 – October 2024 Page 9 of 23

It is the responsibility of the individual to ensure they are using the most up to date PGD.



| Pentazocine | Controlled drug |
|-------------------------|---------------------|
| Pethidine hydrochloride | Controlled drug |
| Pregabalin | Controlled drug |
| Sodium Oxybate | Specialist use only |
| Solriamfetol | Hospital use only |
| Tapentadol | Controlled drug |
| Temazepam | Controlled drug |
| Tramadol | Controlled drug |
| Tryptophan | Specialist use only |

⁵ Patients receiving therapy with Category 1 antiepileptics - phenytoin, carbamazepine, phenobarbital or primidone- should be maintained on their usual brand. Patients receiving therapy with Category 2 antiepileptics - the need for continued supply of a particular manufacturer's product should be based on clinical judgement, taking in to account factors such as seizure frequency and treatment history. (MHRA/CHM-Nov 2013)

⁶ Clobazam can be supplied under the PGD for epilepsy only and must be endorsed SLS.

⁷ Clozapine <u>can</u> be supplied under the PGD if the Pharmacy is registered for the patient monitoring service for that

⁸ Midazolam oromucosal solution can only be supplied under this PGD for the emergency treatment of **status epilepticus**

⁹ All strengths <u>are not</u> allowed on the PGD including oramorph 10mg/5ml



SCHEDULE 5

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Infections, chapter 5

Part A: All medicines in Infections, chapter 5 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Amoebic infection | Fungal infection | Nocturnal Leg Cramps |
|---------------------|------------------|----------------------|
| Bacterial infection | Viral infection | |

Part B: The following medicines listed in Infections, chapter 5 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|---|---------------------------|
| All injections and infusions | Acute/Specialist use only |
| All section 1 | Acute use only |
| All section 4 | Acute use only |
| All section 5 except Quinine for | Acute use only |
| nocturnal leg cramps | |
| All section 6.1 except Molnupiravir for | Specialist use only |
| mild to moderate COVID-19 | |
| All section 6.3a and 6.3b | Specialist use only |
| All section 6.6 | Acute use only |
| Amikacin | Hospital use only |
| Fidaxomicin | Acute use only |
| Delafloxacin | Hospital use only |
| Isavuconazole | Hospital use only |
| Letermovir | Hospital use only |
| Linezolid | Specialist use only |
| Tedizolid | Acute use only |
| Neomycin | Acute use only |
| Posaconazole | Hospital use only |
| Rifaximin | Acute use only |
| Tobramycin | Acute use only |
| Vancomycin | Acute use only |



SCHEDULE 6

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Endocrine system, chapter 6

Part A: All medicines in Endocrine, chapter 6 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Antidiuretic hormone | Bone metabolism disorders | Sex hormone responsive |
|---------------------------|---------------------------|------------------------|
| disorders | | conditions |
| Corticosteroid responsive | Dopamine responsive | Thyroid disorders |
| conditions | conditions | - |
| Diabetes mellitus and | Gonadotrophin responsive | |
| hypoglycaemia | conditions | |

Part B: The following medicines listed in Endocrine system, chapter 6 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|--|--------------------------------------|
| All injections and infusions except in | Acute/Specialist use only/Controlled |
| section 4 | drug |
| Section 3.1 | Specialist use only |
| All section 7 | Specialist use only |
| All section 8.2 except section 8.2a | Controlled drug |
| lodide with iodine | Acute use only |
| Tolvaptan | Hospital use only |



SCHEDULE 7

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Genito-urinary system, chapter 7

Part A: All medicines in Genito-urinary system, chapter 7 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Bladder and urinary | Erectile and ejaculatory |
|---------------------|--------------------------|
| disorders | conditions |
| Contraception | Vaginal and vulval |
| | conditions |

Part B: The following medicines listed in Genito-urinary system, chapter 7 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|-------------------------------------|-----------------------------|
| All injections and infusions except | Acute/Specialist use only |
| Section 3.5 | |
| All intra-uterine devices | Time period between repeats |
| All section 2 | Specialist use only |
| All section 3.2 | Time period between repeats |
| All section 3.3 | Acute use only |
| All section 6 | Specialist use only |



SCHEDULE 8

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Malignant disease, chapter 8

Part A: All medicines in Malignant disease, chapter 8 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Immune system 10 | Malignant disease |
|------------------|-------------------|

Part B: The following medicines listed in Malignant disease, chapter 8 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|---|------------------|
| All Immune System drugs excluded EXCEPT: | Acute/Specialist |
| | use only |
| Azathioprine (oral) for immunosuppression and the treatment of | |
| Crohn's disease, rheumatoid arthritis, Systemic Lupus Erythematosus, | |
| refractory eczema, myasthenia gravis | |
| Ciclosporin (oral) ¹⁰ for immunosuppression and the treatment of | |
| severe ulcerative colitis, severe RA, severe atopic dermatitis, severe | |
| psoriasis, nephrotic syndrome | |
| Sirolimus Taerelimus (erel) 10 | |
| Tacrolimus (oral) 10 Mycophenolate mofetil (oral) | |
| mycophenolate moletii (orai) | |
| All Malignant Disease drugs excluded EXCEPT: | Specialist use |
| | only |
| Mercaptopurine (oral) for the treatment of Crohn's, ulcerative colitis | , |
| Methotrexate (oral and subcutaneous injections for self-administration) | |
| for the treatment of severe Crohn's, severe rheumatoid arthritis, severe | |
| psoriasis | |
| Anastrazole | |
| Bicalutamide | |
| Diethylstibestrol | |
| Enzalutamide ¹¹ | |
| Exemestane | |
| Flutamide | |
| Lanreotide | |
| Letrozole | |
| Megestrol | |
| Tamoxifen | <u> </u> |

¹⁰ Patients receiving oral therapy with ciclosporin or tacrolimus should be maintained on their usual brand. Any change must be under the supervision of a specialist.

¹¹ Enzalutamide can be supplied under the PGD if the patient is within the required monitoring period



SCHEDULE 9

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Blood and nutrition, chapter 9

Part A: All medicines in Blood and nutrition, chapter 9 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Anaemias | Metabolic disorders | Mineral and trace elements deficiencies |
|----------------------------------|---------------------|---|
| Platelet disorders | Nutrition | Vitamin deficiency |
| Fluid and electrolyte imbalances | | |

Part B: The following medicines listed in Blood and nutrition, chapter 9 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|--------------------------------------|---------------------------|
| Blood and blood-forming organs | |
| All injections and infusions except: | Acute/Specialist use only |
| section 1.1 | |
| section 1.3 | |
| | |
| All drugs in section 2 | Specialist use only |
| All drugs in section 3 | Specialist use only |
| All drugs in section 4 | Specialist use only |
| | |
| Nutrition and metabolic disorders | |
| All injections and infusions | Specialist use only |
| section 1 | Specialist use only |
| section 3.4 | |
| section 3.11 | |
| section 3.13 | |
| section 3.14 | |
| section 6.1a | |
| Cinacalcet granules | Hospital use only |
| Eliglustat | Specialist use only |
| Migalastat | Specialist use only |
| Oxymetholone | Controlled Drug |
| Tafamidis | Hospital use only |
| Voxelotor | Hospital use only |



SCHEDULE 10

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Musculoskeletal system, chapter 10

Part A: All medicines in Musculoskeletal, chapter 10 of the current BNF/BNFC ¹², with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Arthritis | Neuromuscular disorders |
|-------------------------|---------------------------|
| Hyperuricaemia and gout | Pain and inflammation in |
| | musculoskeletal disorders |

Part B: The following medicines listed in Musculoskeletal, chapter 10 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|------------------------------|---------------------------|
| All injections and infusions | Acute/Specialist use only |
| All section 3.1 | Hospital use only |
| Amifampridine | Specialist use only |
| Baricitinib | Specialist use only |
| Leflunomide 13 | Monitoring required |
| Tofacitinib | Specialist use only |
| Filgotinib | Specialist use only |
| Upadacitinib | Specialist use only |

¹² Supply of azathioprine, ciclosporin and methotrexate to treat a condition listed in Section A above is allowed under this section of the PGD (see PGD page 14)

¹³ Leflunomide can be supplied under the PGD if the patient is within the required monitoring period



SCHEDULE 11

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Eye, chapter 11

Part A: All medicines in Eye, chapter 11 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Allergic and inflammatory | Eye infections | Glaucoma and ocular |
|---------------------------|----------------|---------------------|
| eye conditions | | hypertension |
| Dry eye conditions | Eye procedures | |

Part B: The following medicines listed in Eye, chapter 11 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|------------------------------|---------------------------|
| All injections and infusions | Acute/Specialist use only |
| All section 4 except: | Acute/Specialist use only |
| Bromfenac | |
| Diclofenac sodium | |
| Flurbiprofen | |
| Ketorolac trometamol | |
| All section 6 | Specialist use only |



SCHEDULE 12

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Ear, nose and oropharynx, chapter 12

Part A: All medicines in Ear, nose and oropharynx, chapter 12 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Dry mouth | Oral hygiene | Oropharyngeal fungal infections |
|---|------------------------------------|---------------------------------|
| Nasal congestion | Otitis media | Oropharyngeal viral infections |
| Nasal inflammation, nasal polyps and rhinitis | Oral ulceration and inflammation | Otitis Externa |
| Nasal staphylococcal infection | Oropharyngeal bacterial infections | |

Part B: The following medicines listed in Ear, nose and oropharynx, chapter 12 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|-------------------|----------------|
| Aluminium acetate | Acute use only |



SCHEDULE 13

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Skin, chapter 13

Part A: All medicines in Skin, chapter 13 of the current BNF/BNFC ¹⁴, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Dry and scaling skin | Sun protection and | Skin cleansers, antiseptics |
|------------------------|---------------------------|-----------------------------|
| disorders | photodamage | and desloughing agents |
| Infections of the skin | Pruritus | Skin disfigurement |
| Inflammatory skin | Rosacea and acne | Superficial soft tissue |
| conditions | | injuries and superficial |
| | | thrombophlebitis |
| Perspiration | Scalp and hair conditions | Warts and calluses |

Part B: The following medicines listed in Skin, chapter 13 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|------------------------------|---------------------------|
| All injections and infusions | Acute/Specialist use only |
| Abrocitinib | Hospital use only |
| Alitretinoin | Specialist use only |
| Isotretinoin | Specialist use only |

¹⁴ Supply of azathioprine, ciclosporin and methotrexate to treat a condition listed in Section A above is allowed under this section of the PGD (see PGD page 14)



SCHEDULE 14

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Vaccines, chapter 14

Part A: All medicines in Vaccines, chapter 14 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, **may** be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

There are no clinical conditions.

Part B: The following medicines listed in Vaccines, chapter 14 of the current BNF/BNFC may not be provided under this PGD.

| Excluded drug | Rationale |
|----------------|---------------------------|
| All chapter 14 | Acute/Specialist use only |



SCHEDULE 15

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Anaesthesia, chapter 15

Part A: All medicines in Anaesthesia, chapter 15 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, **may** be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| 1 1 1 | |
|-------------------|--|
| Local anaesthesia | |
| Lucai anacsincsia | |

Part B: The following medicines listed in Anaesthesia, chapter 15 of the current BNF/BNFC **may not** be provided under this PGD.

| Excluded drug | Rationale |
|--|---------------------------|
| All chapter 15 except : | Acute/Specialist use only |
| Lidocaine hydrochloride cream, ointment, plaster and spray | |
| Lidocaine with prilocaine cream | |
| Tetracaine gel | |



SCHEDULE 16

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Emergency treatment of poisoning, chapter 16

Part A: All medicines in Emergency treatment of poisoning, chapter16 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, **may** be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

| Management of opioid overdose | |
|-------------------------------|--|
| | |

Part B: The following medicines listed in Emergency treatment of poisoning, chapter 16 of the current BNF/BNFC **may not** be provided under this PGD.

| Excluded drug | Rationale |
|------------------------|---------------------------|
| All chapter 16 except: | Acute/Specialist use only |
| Naloxone hydrochloride | |



SCHEDULE 17

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Borderline Substances, appendix 2

Part A: All products in the Borderline Substances section, appendix 2 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions: ¹⁵

| Disease-related malnutrition | Intractable malabsorption | Pre-operative preparation of malnourished patients |
|---------------------------------|---|--|
| Dysphagia | Proven inflammatory bowel disease | Following total gastrectomy |
| Short-bowel syndrome | Bowel fistula | Photodermatoses (skin protection in) |
| Dermatitis, eczema and pruritis | Disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitiligo | Dry mouth (xerostomia) |

Part B: The following medicines listed in Borderline Substances, appendix 2 of the current BNF/BNFC may not be provided under this PGD.

There are no exclusions

¹⁵ All items supplied from this section under the PGD **must be endorsed ACBS.** If required, refer to Scottish Drug Tariff section 16 for current list of allowable gluten-free products